Epidemiology and burden of alopecia areata: A systematic review

Alexandra C. Villasante Fricke, Mariya Miteva

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Alopecia areata (AA) is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair that can be psychologically devastating. AA is clinically heterogenous, and its natural history is unpredictable. There is no preventative therapy or cure. Objective: The objective of this study is to provide an evidence-based systematic review on the epidemiology and the burden of AA. Methods and selection criteria: A search was conducted of the published, peer-reviewed literature via PubMed, Embase, and Web of Science. Studies published in English within the last 51 years that measured AA’s incidence, prevalence, distribution, disability-adjusted life years (DALYs), quality of life, and associated psychiatric and medical comorbidities were included. Two authors assessed studies and extracted the data. Results: The lifetime incidence of AA is approximately 2% worldwide. Both formal population studies found no sex predominance. First onset is most common in the third and fourth decades of life but may occur at any age. An earlier age of first onset corresponds with an increased lifetime risk of extensive disease. Global DALYs for AA were calculated at 1,332,800 in 2010. AA patients are at risk for depression and anxiety, atopy, vitiligo, thyroid disease, and other autoimmune conditions. Conclusion: AA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approximately 2%. AA is associated with psychiatric and medical comorbidities including depression, anxiety, and several autoimmune disorders, and an increased global burden of disease.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalClinical, Cosmetic and Investigational Dermatology
Volume8
DOIs
StatePublished - Jul 24 2015

Fingerprint

Alopecia Areata
Epidemiology
Alopecia
Quality-Adjusted Life Years
Psychiatry
Comorbidity
Anxiety
Depression
Vitiligo
Thyroid Diseases
Incidence
Scalp
Natural History
Age of Onset
PubMed
Hair
Patient Selection
Population
Quality of Life

Keywords

  • Burden of disease
  • Hair
  • Hair loss
  • Incidence
  • Prevalence

ASJC Scopus subject areas

  • Dermatology

Cite this

Epidemiology and burden of alopecia areata : A systematic review. / Villasante Fricke, Alexandra C.; Miteva, Mariya.

In: Clinical, Cosmetic and Investigational Dermatology, Vol. 8, 24.07.2015, p. 397-403.

Research output: Contribution to journalArticle

@article{789e6535fbd04f0885665de68a8a9278,
title = "Epidemiology and burden of alopecia areata: A systematic review",
abstract = "Background: Alopecia areata (AA) is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair that can be psychologically devastating. AA is clinically heterogenous, and its natural history is unpredictable. There is no preventative therapy or cure. Objective: The objective of this study is to provide an evidence-based systematic review on the epidemiology and the burden of AA. Methods and selection criteria: A search was conducted of the published, peer-reviewed literature via PubMed, Embase, and Web of Science. Studies published in English within the last 51 years that measured AA’s incidence, prevalence, distribution, disability-adjusted life years (DALYs), quality of life, and associated psychiatric and medical comorbidities were included. Two authors assessed studies and extracted the data. Results: The lifetime incidence of AA is approximately 2{\%} worldwide. Both formal population studies found no sex predominance. First onset is most common in the third and fourth decades of life but may occur at any age. An earlier age of first onset corresponds with an increased lifetime risk of extensive disease. Global DALYs for AA were calculated at 1,332,800 in 2010. AA patients are at risk for depression and anxiety, atopy, vitiligo, thyroid disease, and other autoimmune conditions. Conclusion: AA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approximately 2{\%}. AA is associated with psychiatric and medical comorbidities including depression, anxiety, and several autoimmune disorders, and an increased global burden of disease.",
keywords = "Burden of disease, Hair, Hair loss, Incidence, Prevalence",
author = "{Villasante Fricke}, {Alexandra C.} and Mariya Miteva",
year = "2015",
month = "7",
day = "24",
doi = "10.2147/CCID.S53985",
language = "English (US)",
volume = "8",
pages = "397--403",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Epidemiology and burden of alopecia areata

T2 - A systematic review

AU - Villasante Fricke, Alexandra C.

AU - Miteva, Mariya

PY - 2015/7/24

Y1 - 2015/7/24

N2 - Background: Alopecia areata (AA) is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair that can be psychologically devastating. AA is clinically heterogenous, and its natural history is unpredictable. There is no preventative therapy or cure. Objective: The objective of this study is to provide an evidence-based systematic review on the epidemiology and the burden of AA. Methods and selection criteria: A search was conducted of the published, peer-reviewed literature via PubMed, Embase, and Web of Science. Studies published in English within the last 51 years that measured AA’s incidence, prevalence, distribution, disability-adjusted life years (DALYs), quality of life, and associated psychiatric and medical comorbidities were included. Two authors assessed studies and extracted the data. Results: The lifetime incidence of AA is approximately 2% worldwide. Both formal population studies found no sex predominance. First onset is most common in the third and fourth decades of life but may occur at any age. An earlier age of first onset corresponds with an increased lifetime risk of extensive disease. Global DALYs for AA were calculated at 1,332,800 in 2010. AA patients are at risk for depression and anxiety, atopy, vitiligo, thyroid disease, and other autoimmune conditions. Conclusion: AA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approximately 2%. AA is associated with psychiatric and medical comorbidities including depression, anxiety, and several autoimmune disorders, and an increased global burden of disease.

AB - Background: Alopecia areata (AA) is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair that can be psychologically devastating. AA is clinically heterogenous, and its natural history is unpredictable. There is no preventative therapy or cure. Objective: The objective of this study is to provide an evidence-based systematic review on the epidemiology and the burden of AA. Methods and selection criteria: A search was conducted of the published, peer-reviewed literature via PubMed, Embase, and Web of Science. Studies published in English within the last 51 years that measured AA’s incidence, prevalence, distribution, disability-adjusted life years (DALYs), quality of life, and associated psychiatric and medical comorbidities were included. Two authors assessed studies and extracted the data. Results: The lifetime incidence of AA is approximately 2% worldwide. Both formal population studies found no sex predominance. First onset is most common in the third and fourth decades of life but may occur at any age. An earlier age of first onset corresponds with an increased lifetime risk of extensive disease. Global DALYs for AA were calculated at 1,332,800 in 2010. AA patients are at risk for depression and anxiety, atopy, vitiligo, thyroid disease, and other autoimmune conditions. Conclusion: AA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approximately 2%. AA is associated with psychiatric and medical comorbidities including depression, anxiety, and several autoimmune disorders, and an increased global burden of disease.

KW - Burden of disease

KW - Hair

KW - Hair loss

KW - Incidence

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=84938236167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938236167&partnerID=8YFLogxK

U2 - 10.2147/CCID.S53985

DO - 10.2147/CCID.S53985

M3 - Article

AN - SCOPUS:84938236167

VL - 8

SP - 397

EP - 403

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -